Results from the United Kingdom-led PEACOCC phase II trial regarding the benefits of pembrolizumab on clear cell gynecological cancers was recently published in JAMA Oncology. According to the study authors, "less than 5% of clear cell gynaecological cancers" are attributed to the vagina, vulva, and cervix. While this clear-cell histological subtype is rare, the authors are adamant that "tissue collection including contemporaneous trial biopsies allows further translational study of the molecular and immune landscape."
To learn more about the PEACOCC trial, click here.
Source mentioned:
Kristeleit R, Devlin M-J, Clamp A, et al. Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer A Phase 2 Nonrandomized Clinical Trial. JAMA Oncology; Published online 6 February 2025. doi:10.1001/jamaoncol.2024.6797
No comments:
Post a Comment